ANDOVER, Mass. -- Bayer Environmental Science announces the nationwide launch of the Maxforce Tick Management System in more than a dozen states affected by Lyme disease, from Maine to Virginia to Illinois. The product dramatically reduces tick populations and the risk of Lyme disease by treating the primary hosts of the disease - the
field mouse and chipmunk.
In field trials that began in 1999, researchers from the Centers for
Disease Control and Prevention (CDC) and Bayer scientists tested the product
on hundreds of residential properties in Connecticut, Massachusetts, New York,
and New Jersey. The results showed nearly an 80 percent reduction in the nymphal
tick populations after the first year and a 96 percent reduction over two years.
Maxforce TMS is the first product since the isolation of the Lyme bacteria
20 years ago that effectively reduces the population of ticks and the spread
of Lyme disease, by interrupting the cycle of the disease.
"Five years ago we partnered with the CDC to develop and test a product
that would control ticks and reduce the risk of Lyme disease and other tick-
borne infections," said Chuck Cole, marketing manager for the Maxforce Tick
Management System. "The product has withstood the test of time. It's a great
example of how a public-private collaborative effort can address a public
health issue and make a positive impact on people's lives."
"Before the trials, we were constantly doing tick checks and removing
attached deer ticks from the children and from ourselves," said Lesley Trevor,
a Connecticut homeowner who participated in the field trials. "Now we still
do a nightly tick check, but we rarely, if ever, find a tick on the children,
on ourselves or in the house. The bait boxes have made an incredible
difference in the quality of our life."
According to the CDC, more than 23,000 human cases of Lyme disease were
recorded in 2002, with an estimated 9 out of 10 cases going unreported. Once
infected with Lyme disease, a person may experience flu-like symptoms and
develop a red rash in the shape of a bull's eye. Because the symptoms of Lyme
disease so closely mimic the flu, it often goes undiagnosed and can lead to
more serious health problems if left untreated.
Contrary to popular belief, small rodents, not deer, are responsible for
transmitting the Lyme disease bacteria to ticks. By treating the rodents in
and around residential properties, Maxforce TMS gets to the root of the
problem and breaks the cycle of Lyme disease.
Hatched disease-free, ticks feed off small rodents in their first (larval)
stage of life, when many are infected with Lyme disease and other tick-borne
infections. Now carrying the bacteria, ticks in the second (nymphal) stage
feed once again, mainly on rodents but also on humans. The danger is that
ticks in this second stage are very small and therefore, not easily detected
and removed. This makes the chances of contracting Lyme disease and other
tick-borne infections greater for humans.
"The Maxforce Tick Management System kills ticks during the critical
larval and nymphal stages when they contract the Lyme bacteria and other tick-
borne infections from small rodents," said Cole.
More than 75 percent of Lyme disease cases are contracted within 100 feet of the
home. The Maxforce Tick Management System consists of a small, child-
resistant box with an insecticide. Boxes are placed around the perimeter of
residential properties to control the ticks that live on small rodents. The
Maxforce Tick Management System works by treating mice and chipmunks that
enter each box with a small dose of insecticide. If left untreated, a typical
field mouse can carry more than 150 ticks during peak tick-activity periods,
and all of these ticks have the potential to infect people with Lyme disease
and other tick-borne infections. The active ingredient in the insecticide --
fipronil -- is one of the world's leading insecticides, often used in flea and
tick control products for pets.
The Maxforce Tick Management System has received federal approval and is
currently registered in Connecticut, the District of Columbia, Delaware,
Illinois, Massachusetts, Maryland, Maine, Minnesota, New Hampshire, New
Jersey, Ohio, Pennsylvania, Rhode Island, Virginia, Vermont, and Wisconsin.
Additional states are expected to register the product in coming months.
Source: Bayer Environmental Science
Genomic Surveillance A New Frontier in Health Care Outbreak Detection
November 27th 2024According to new research, genomic surveillance is transforming health care-associated infection detection by identifying outbreaks earlier, enabling faster interventions, improving patient outcomes, and reducing costs.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.